Targeted insight is essential for making informed decisions in the drug design process. Which parameters are driving the biological activity of my compound series? While this can still be assessed relatively easily for a small number of compounds, establishing SARs across a compound series spanning multiple scaffolds and chemotypes becomes far more challenging. This is exactly where the latest release of our drug design dashboard comes in: SeeSAR 15 ‘Apollo’.
In this webinar, we will showcase the new Activity Spotter mode, which identifies the 3D features that drive or prevent biological activity across a series of aligned molecules. We will also explore additional new developments in SeeSAR 15, including loop modeling, quality-of-life improvements to hydrogen-bond interaction visualization, multiple-template docking, MPO scoring, and resource-efficient molecule filtering.
We look forward to presenting and discussing the 50th release of SeeSAR with you.
You can find the full changelog following this link.
